11/21
07:00 am
uncy
Unicycive Therapeutics to Participate in Two Upcoming Investor Conferences Including a Fireside Chat at the Piper Sandler 36th Annual Healthcare Conference
Low
Report
Unicycive Therapeutics to Participate in Two Upcoming Investor Conferences Including a Fireside Chat at the Piper Sandler 36th Annual Healthcare Conference
11/13
07:15 am
uncy
Unicycive Announces Third Quarter 2024 Financial Results and Provides Business Update
Medium
Report
Unicycive Announces Third Quarter 2024 Financial Results and Provides Business Update
11/12
08:33 am
uncy
Unicycive Therapeutics, Inc. (NASDAQ: UNCY) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $2.50 price target on the stock.
High
Report
Unicycive Therapeutics, Inc. (NASDAQ: UNCY) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $2.50 price target on the stock.
11/11
07:00 am
uncy
Unicycive Therapeutics Announces U.S. FDA Acceptance of the New Drug Application (NDA) for Oxylanthanum Carbonate (OLC) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis
High
Report
Unicycive Therapeutics Announces U.S. FDA Acceptance of the New Drug Application (NDA) for Oxylanthanum Carbonate (OLC) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis
10/28
07:06 am
uncy
Unicycive Therapeutics Delivers Multiple Poster Presentations Highlighting Development Progress on Oxylanthanum Carbonate (OLC) and UNI-494 at the American Society of Nephrology (ASN) Kidney Week 2024 [Yahoo! Finance]
High
Report
Unicycive Therapeutics Delivers Multiple Poster Presentations Highlighting Development Progress on Oxylanthanum Carbonate (OLC) and UNI-494 at the American Society of Nephrology (ASN) Kidney Week 2024 [Yahoo! Finance]
10/28
07:03 am
uncy
Unicycive Therapeutics Delivers Multiple Poster Presentations Highlighting Development Progress on Oxylanthanum Carbonate (OLC) and UNI-494 at the American Society of Nephrology (ASN) Kidney Week 2024
High
Report
Unicycive Therapeutics Delivers Multiple Poster Presentations Highlighting Development Progress on Oxylanthanum Carbonate (OLC) and UNI-494 at the American Society of Nephrology (ASN) Kidney Week 2024
10/16
04:35 pm
uncy
Unicycive Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on October 17, 2024
High
Report
Unicycive Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on October 17, 2024
10/16
12:03 pm
uncy
Results of Phase I trial shed positive light on UNI-494 for acute kidney injury [Yahoo! Finance]
Low
Report
Results of Phase I trial shed positive light on UNI-494 for acute kidney injury [Yahoo! Finance]
10/14
07:03 am
uncy
Unicycive Therapeutics Announces Late-Breaker Poster Presentation on Oxylanthanum Carbonate (OLC) at the American Society of Nephrology (ASN) Kidney Week 2024
Low
Report
Unicycive Therapeutics Announces Late-Breaker Poster Presentation on Oxylanthanum Carbonate (OLC) at the American Society of Nephrology (ASN) Kidney Week 2024
10/9
03:48 pm
uncy
Unicycive Therapeutics, Inc. (NASDAQ: UNCY) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $2.50 price target on the stock.
Low
Report
Unicycive Therapeutics, Inc. (NASDAQ: UNCY) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $2.50 price target on the stock.
10/9
07:08 am
uncy
Unicycive Therapeutics Successfully Completes UNI-494 Phase 1 Study in Healthy Volunteers [Yahoo! Finance]
Medium
Report
Unicycive Therapeutics Successfully Completes UNI-494 Phase 1 Study in Healthy Volunteers [Yahoo! Finance]
10/9
07:03 am
uncy
Unicycive Therapeutics Successfully Completes UNI-494 Phase 1 Study in Healthy Volunteers
Low
Report
Unicycive Therapeutics Successfully Completes UNI-494 Phase 1 Study in Healthy Volunteers
9/24
07:03 am
uncy
Unicycive Therapeutics to Participate in a Fireside Chat at the Virtual Lytham Partners Fall 2024 Investor Conference on October 1, 2024
Low
Report
Unicycive Therapeutics to Participate in a Fireside Chat at the Virtual Lytham Partners Fall 2024 Investor Conference on October 1, 2024
9/16
07:03 am
uncy
Unicycive Therapeutics to Present at the Virtual Life Sciences Investor Forum on September 19, 2024
Medium
Report
Unicycive Therapeutics to Present at the Virtual Life Sciences Investor Forum on September 19, 2024
9/6
08:08 am
uncy
Unicycive Therapeutics, Inc. (NASDAQ: UNCY) had its "speculative buy" rating re-affirmed by analysts at Benchmark Co.. They now have a $3.00 price target on the stock.
Medium
Report
Unicycive Therapeutics, Inc. (NASDAQ: UNCY) had its "speculative buy" rating re-affirmed by analysts at Benchmark Co.. They now have a $3.00 price target on the stock.
9/5
07:03 am
uncy
Unicycive Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Medium
Report
Unicycive Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
9/3
11:19 am
uncy
Unicycive Therapeutics, Inc. (NASDAQ: UNCY) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $2.50 price target on the stock.
Medium
Report
Unicycive Therapeutics, Inc. (NASDAQ: UNCY) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $2.50 price target on the stock.
9/3
07:08 am
uncy
Unicycive Therapeutics Announces Submission of the New Drug Application (NDA) to the U.S. FDA for Oxylanthanum Carbonate (OLC) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis [Yahoo! Finance]
High
Report
Unicycive Therapeutics Announces Submission of the New Drug Application (NDA) to the U.S. FDA for Oxylanthanum Carbonate (OLC) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis [Yahoo! Finance]
9/3
07:03 am
uncy
Unicycive Therapeutics Announces Submission of the New Drug Application (NDA) to the U.S. FDA for Oxylanthanum Carbonate (OLC) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis
Medium
Report
Unicycive Therapeutics Announces Submission of the New Drug Application (NDA) to the U.S. FDA for Oxylanthanum Carbonate (OLC) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis
8/26
07:18 am
uncy
Unicycive Therapeutics to Present Three Posters at the American Society of Nephrology (ASN) Kidney Week 2024 [Yahoo! Finance]
Medium
Report
Unicycive Therapeutics to Present Three Posters at the American Society of Nephrology (ASN) Kidney Week 2024 [Yahoo! Finance]
8/26
07:03 am
uncy
Unicycive Therapeutics to Present Three Posters at the American Society of Nephrology (ASN) Kidney Week 2024
Medium
Report
Unicycive Therapeutics to Present Three Posters at the American Society of Nephrology (ASN) Kidney Week 2024